Oral Health and Lymphoma

When patients are receiving chemotherapy or radiotherapy, the local defense mechanisms in the mouth are reduced. This means that oral infections are common.


Oral candidosis (also known as ‘thrush’) is the most common type of infection. Symptoms include:


• Discomfort with the white plaques adhering to the lining of the mouth

• Redness at the lining of the mouth which can be difficult to detect

• Sores at the corners of the mouth

• Sometimes, there may be a complete lack of symptoms and the presence of infection may simply be detected when you visit your doctor or dentist


Because it is so common, sometimes health care providers will give medications to prevent it, instead of treating it only when signs and symptoms develop. In fact, 90% of people who are immuno-compromised will have oral health problems. So if you undergoing treatment, don’t take chances with your teeth and gums – see your dentist regularly.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap